Health
Biotechnology
Therapy
Amicus Therapeutics
$12.099876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$12.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.31 (2.61%) Today
-$0.09 (-0.74%) After Hours
Why Robinhood?
You can buy or sell FOLD and other stocks, options, ETFs, and crypto commission-free!
About
Amicus Therapeutics, Inc. engages in the discovery, developmen0t, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. Read More The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
Employees
508
Headquarters
Cranbury, New Jersey
Founded
2002
Market Cap
2.80B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.62M
High Today
$12.18
Low Today
$11.94
Open Price
$11.94
Volume
640.76K
52 Week High
$17.62
52 Week Low
$8.27
Collections
Health
Biotechnology
Therapy
Technology
US
North America
News
Seeking AlphaMay 23
Amicus Therapeutics: Galafold Doing Better Than Q1 Revenues Suggest
The company added 150 new patients in Q1, more than the total number of patients treated in the first twelve months of the EU launch.
Yahoo FinanceMay 10
Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
CRANBURY, N.J., May 10, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Tuesday, May 14, 2019 at 1:00 p.m. PT. A live audio webcast of the presentation can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations , and will be...
Yahoo FinanceMay 9
Amicus' Earnings & Revenues Miss Estimates in Q1
Amicus Therapeutics, Inc. FOLD reported loss of 39 cents per share in the first quarter of 2019 (excluding loss on exchange of convertible notes), wider than the year-ago loss of 28 cents and the Zacks Consensus Estimate of a loss of 31 cents. Total revenues in the first quarter were $34 million, reflecting 104% surge from $16.7 million in the year-ago quarter. The figure missed the Zacks Consensus Estimate of $38 million. The company realized revenues from commercial sales of its only marketed drug, Galaf...
Price Paid on Robinhood
0% Higher
Right Now
52 Week Low
$8.27
Average Price Paid
$12.08
52 Week High
$17.62
Earnings
-$0.41
-$0.37
-$0.32
-$0.28
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, Pre-Market